摘要
目的观察比较恩替卡韦分散片单用与联合扶正化瘀胶囊两种方法对乙型肝炎肝纤维化的疗效。方法60例乙型肝炎肝硬化患者随机分为两组,各30例,A组单独接受恩替卡韦分散片治疗,B组接受恩替卡韦分散片治疗的同时联合扶正化瘀胶囊抗病毒药物治疗,两组在护肝治疗上亦相同。结果 A组治疗前透明质酸(HA)、Ⅲ型前胶原(PCⅢ)、层粘连蛋白(LN)分别为(253.8±50.2)、(245.3±63.2)、(153.8±54.2)ng/L,B组治疗前HA、PCⅢ、LN分别为(248.8±47.2)、(257.3±74.2)、(154.3±53.2)ng/L,两组比较差异无统计学意义(P>0.05);A组治疗后HA、PCⅢ、LN分别为(136.8±41.2)、(146.5±44.2)、(123.4±23.4)ng/L,B组治疗后HA、PCⅢ、LN分别为(101.4±33.2)、(108.4±38.8)、(78.4±12.9)ng/L,两组比较差异有统计学意义(P<0.05);A组的HBV-DNA阴转率为90.0%,B组的HBV-DNA阴转率为93.0%,两组比较差异无统计学意义(P>0.05)。结论恩替卡韦分散片联合扶正化瘀胶囊治疗肝纤维化疗效优于单药恩替卡韦分散片治疗。
Objective To observe the therapeutic effect of Entecavir treatment with Fuzheng Huayu Capsules to chron ic hepatitis B liver fibrosis.Methods 60 patients with chronic hepatitis B liver fibrosis were divided into group A（n= 30） and B（n=30） randomly.The group A was given Entecavir Dispersible Tablets lonely,the group B was given Ente cavir Dispersible Tablets and Fuzheng Huayu Capsules for antiviral therapy,and the two groups were given the same liver-protecting therapy.Results Before treatment,the level of hyaluronic acid [HA,（253.8 ±50.2） ng/L],type Ⅲ procollagen [PCⅢ,（245.3±63.2） ng/L],laminin [LN,153.8 ±54.2） ng/L] in group A were not statically different from the level of HA [（248.8±47.2） ng/L],PCⅢ [（257.3±74.2） ng/L],LN [（154.3±53.2） ng/L] in group B（P 0.05）.After treatment,the level of HA [（136.8±41.2） ng/L],PCⅢ [（146.5±44.2） ng/L],LN [（123.4±23.4） ng/L] in group A were statically different from the level of HA [（101.4 ±33.2） ng/L],PCⅢ [（108.4±38.8） ng/L],LN [（78.4±12.9） ng/L] in group B（P 0.05）.The negative conversion rate of HBV-DNA in group A was 90.0%,which was not significantly different from that（93.0%） in group B（P 0.05）.Conclusion The therapy of Entecavir Dispersible Tablets with Fuzheng Huayu Capsules for chronic hepatitis B liver fibrosis is better than that of Entecavir Dispersible Tablets lonely.
出处
《中国医药导报》
CAS
2013年第23期88-90,共3页
China Medical Herald
基金
国家自然科学基金资助项目(编号81260284)
关键词
乙型肝炎
恩替卡韦分散片
扶正化瘀胶囊
肝纤维化
Hepatitis B
Entecavir Dispersible Tablets
Fuzheng Huayu Capsules
Liver fibrosis
